Part 2: Purifii™ Upper Air UVGI: Proven Efficacy

Aesthetically pleasing without the potential dangers of mercury — Luminii’s upper air UVGI system is a powerful tool in the “fight” against airborne pathogens like COVID-19 (SARS-CoV-2), but how does it fare in testing?

To prove the efficacy of the Purifii upper air UVGI system, Innovative Bioanalysis, a third-party BSL3 lab, tested the system under laboratory conditions that simulate an interior architectural environment. The lab performed three sets of experiments that demonstrated the system’s effectiveness at inactivating COVID-19, including a large reduction in virus present. 

First Set of Testing

The first set of testing evaluated the 275nm LED’s effectiveness at inactivating virus on a surface. The experimental procedure consisted of two control slides and two experimental slides, with each group exposed to a different dose of UV. Glass slides were inoculated with a high concentration of viral media and allowed to dry for 11 minutes. 

The experimental samples were then exposed to a dose of the UV. The slides were then rinsed with a viral media solution and analyzed for remaining viral concentration. 

How did Luminii net out? In 60 seconds, the lower driver saw a surface reduction of 99.96 percent; the high driver saw a 99.99 percent reduction.

Second Set of Testing — Purifii AER W

The second set of testing evaluated the Purifii AER W device’s efficacy against aerosolized COVID-19. The testing was performed in an 8’W x 8’H x 10’L sealed chamber with the fixture mounted centered on one 8’ wall. The air in the chamber was mixed using a customized system designed to simulate airflow

from an HVAC system. 

Unlike typical HVAC systems that exhaust a portion of circulated air, the custom system only re-circulated air within the room to create a well-mixed space for testing. Testing was performed by nebulizing a viral stock in the room to a concentration of 6.32 X 10^6 TCID50/mL. 

A control test was performed with only the air flow system running, and the experimental test was performed with both the air flow system and the UV upper air device running. Samples were taken at five minutes, 10 minutes, and 30 minutes through a vacuum sampling system and incubated to report viral inactivation. 

The result? There was a 99.38 percent reduction in aerosol activation within five minutes; 99.98 percent reduction within 10 minutes; and 99.99 percent within 30 minutes.

Third Set of Testing — No Air Mixing

The third set of testing used a larger 8’W x 8’H x 20’L chamber with one AER W fixture mounted on each 8’ wall. For this test, there was no air mixing in the chamber during the experiment. Testing was performed by nebulizing a viral stock in the room to a concentration of 6.32 X 10^6 TCID50/mL. One control test was

performed by running the test with the AER W fixtures off, and the experimental test was performed with both fixtures on. The result was a 99.998 percent reduction within 20 minutes.

Proven efficacy against COVID-19 in the lab thus served to vet the Purifii platform for immediate use on the front lines of the COVID-19 pandemic — and in the control of various known and novel airborne pathogens in the future including the seasonal flu.